研究業績

Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, Kurose N, Miura K, Nakamura S, Aoki S, on behalf of Japanese TAFRO Syndrome Research Team. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. International Journal of Hematology. 2020 Jan;111(1):155-158. DOI: 10.1007/s12185-019-02780-1
Koga T, Sumiyoshi R, Kawakami A and Yoshizaki K. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. Modern Rheumatology. 2018 Oct; DOI: 10.1080/14397595.2018.1532383
Frits van Rhee, Peter Voorhees, Angela Dispenzieri, Alexander Fosså, Gordan Srkalovic, Makoto Ide, Nikhil Munshi, Stephen Schey, Matthew Streetly, Sheila K. Pierson, Helen L. Partridge, Sudipto Mukherjee, Dustin Shilling, Katie Stone, Amy Greenway, Jason Ruth, Mary Jo Lechowicz, Shanmuganathan Chandrakasan, Raj Jayanthan, Elaine S. Jaffe, Heather Leitch, Naveen Pemmaraju, Amy Chadburn, Megan S. Lim, Kojo S. Elenitoba-Johnson, Vera Krymskaya, Aaron Goodman, Christian Hoffmann, Pier Luigi Zinzani, Simone Ferrero, Louis Terriou, Yasuharu Sato, David Simpson, Raymond Wong, Jean-Francois Rossi, Sunita Nasta,30 Kazuyuki Yoshizaki, Razelle Kurzrock, Thomas S. Uldrick, Corey Casper, Eric Oksenhendler, and David C. Fajgenbaum International, Evidence-based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease. Blood First Edition Paper, prepublished online September 4, 2018; DOI 10.1182/blood-2018-07-862334
Fujimoto S, Koga T, Kawakami A, Kawabata H, Okamoto S, Mizuki M, Yano S, Ide M, Uno K, Yagi K, Kojima T, Mizutani M, Tokumine Y, Nishimoto N, Fujiwara H, Nakatsuka SI, Shiozawa K, Iwaki N, Masaki Y, Yoshizaki K. Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. Mod Rheumatol. 2017 Sep; 7:1-7.
井出眞, 横山倫子, 吉崎和幸. キャッスルマン病におけるトシリズマブの使い方と注意点. リウマチ科. 2018-08; 60(2):124-132.
角田慎一郎, 吉崎和幸. Castleman病の診断と治療の進歩 (特集多発性骨髄腫 : 基礎・臨床研究の最新動向) -- (特論) . 日本臨床 = Japanese journal of clinical medicine 2018-07;76(7), 1256-1261.
Koga T, Fujimoto S, Kawakami A, Kawabata H, Masaki Y, Kishimoto T, Yoshizaki K. Therapeutic outlook for Castleman’s disease: prospects for the next decade. Expert Opinion on Orphan Drugs. 2017 Jul; 5(8):633-640.
吉崎和幸, 岡本真一郎, 川端浩, 水木満佐央, 川上純, 正木康史, 矢野真吾, 井出眞, 宇野賀津子, 八木克巳, 小島俊行, 水谷実, 徳嶺進洋, 西本憲弘, 藤原寛, 中塚伸一, 塩沢和子, 岩城憲子, 古賀智裕.　キャッスルマン病診療の参照ガイド.　臨床血液. 2017; 58: 97-107.　http://doi.org/10.11406/rinketsu.58.97
Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi , JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 Mar 23; 129(12): 1646–1657. Prepublished online 2017 Jan 13. doi: 10.1182/blood-2016-10-746933.